AmeriCann, Inc., a specialized cannabis company, develops product manufacturing and greenhouse cultivation facilities in the United States. More Details
+ 1 more risk
Overvalued with worrying balance sheet.
Share Price & News
How has AmeriCann's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ACAN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ACAN underperformed the US Pharmaceuticals industry which returned 12.4% over the past year.
Return vs Market: ACAN underperformed the US Market which returned 19.5% over the past year.
Price Volatility Vs. Market
How volatile is AmeriCann's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is AmeriCann undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ACAN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ACAN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ACAN is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: ACAN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ACAN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ACAN is good value based on its PB Ratio (1.5x) compared to the US Pharmaceuticals industry average (3.2x).
How is AmeriCann forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AmeriCann has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of ACAN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access AmeriCann's filings and announcementshere.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has AmeriCann performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACAN is currently unprofitable.
Growing Profit Margin: ACAN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACAN is unprofitable, and losses have increased over the past 5 years at a rate of 16.1% per year.
Accelerating Growth: Unable to compare ACAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.6%).
Return on Equity
High ROE: ACAN has a negative Return on Equity (-49.24%), as it is currently unprofitable.
How is AmeriCann's financial position?
Financial Position Analysis
Short Term Liabilities: ACAN's short term assets ($218.1K) do not cover its short term liabilities ($303.7K).
Long Term Liabilities: ACAN's short term assets ($218.1K) do not cover its long term liabilities ($8.2M).
Debt to Equity History and Analysis
Debt Level: ACAN's debt to equity ratio (63.9%) is considered high.
Reducing Debt: ACAN's debt to equity ratio has reduced from 105.9% to 63.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACAN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ACAN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 39.7% each year
What is AmeriCann current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACAN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACAN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACAN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACAN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACAN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Tim Keogh (40 yo)
Mr. Timothy Ryan Keogh, also known as Tim, has been the Chief Executive Officer of Americann, Inc. since March 25, 2014 and serves as its President. Prior to joining AmeriCann, Mr. Keogh was the Chief Exec ...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD454.40K) is about average for companies of similar size in the US market ($USD585.94K).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
|CEO, President & Director||6.58yrs||US$454.40k||5.13% |
|Extraction & Infused Product Advisor and Member of Advisory Board||4.92yrs||no data||no data|
|Genetics & Breeding Advisor and Member of Advisory Board||no data||no data||no data|
|Medical Advisor & Member of Advisory Board||no data||no data||no data|
|Licensing & Compliance Advisor and Member of Advisory Board||no data||no data||no data|
|Independent Director||1.75yrs||US$270.60k||0.11% |
Experienced Board: ACAN's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AmeriCann, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: AmeriCann, Inc.
- Ticker: ACAN
- Exchange: OTCPK
- Founded: 2010
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$9.755m
- Shares outstanding: 23.50m
- Website: https://www.americann.co
Number of Employees
- AmeriCann, Inc.
- 1550 Wewatta Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ACAN||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Sep 2013|
AmeriCann, Inc., a specialized cannabis company, develops product manufacturing and greenhouse cultivation facilities in the United States. It intends to offer a package of services that includes consultin ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/20 00:12|
|End of Day Share Price||2020/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.